Brentuximab vedotin triggers apoptosis of PEL cells. Lymphoma cell lines lacking CD30 expression WSU-NHL (A) and Raji (B) and CD30-expressing PEL cell lines BC-1 (C), BC-3 (D), UM-PEL-1c (E), and UM-PEL-3c (F) were treated with increasing concentrations of brentuximab vedotin (B.V.) or Ig-VcMMAE. At 72 hours after treatment, cell viability was determined by flow cytometry following YO-PRO and propidium iodide staining. Experiments depicted in panels A-E were repeated thrice independently in triplicate. The representative data from one experiment are shown. Error bars correspond to the standard error of the mean in all graphs.